LRRK2 variants are proposed to modify PD risk by regulating the enzyme’s kinase activity, as most pathogenic variants lead to increased kinase activity, and emerging evidence suggests that the protective variant is associated with reduced activity [19–21]. The gene discussed is LRRK2; the disease is Parkinson disease.